Published in Br J Cancer on July 01, 2000
A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer (2004) 1.17
The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study. Br J Cancer (2010) 0.93
Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. Br J Cancer (2003) 0.86
Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer. Braz J Med Biol Res (2013) 0.81
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. Br J Cancer (2007) 0.81
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. J Cancer Res Clin Oncol (2010) 0.80
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial. BMC Cancer (2011) 0.80
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer. J Urol (2009) 0.80
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Invest New Drugs (2010) 0.77
Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients. Int J Clin Oncol (2012) 0.76
Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells. Mol Biol Rep (2010) 0.75
Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer. Br J Cancer (2001) 0.75
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol (1999) 3.62
Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res (1998) 2.22
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther (1991) 2.06
Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem (1991) 1.98
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol (1998) 1.72
Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res (1993) 1.56
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.56
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol (1995) 1.49
Peripheral neurotoxicity induced by docetaxel. Neurology (1996) 1.42
Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol (1993) 1.32
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) Br J Cancer (1994) 1.30
Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. J Natl Cancer Inst (1993) 1.22
Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol (1994) 1.21
Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res (1993) 1.18
Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol (1994) 1.16
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol (1995) 1.16
Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst (1992) 1.12
Coping with toxicities of docetaxel (Taxotere). Ann Oncol (1993) 1.06
Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer (1994) 1.05
Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (1997) 1.02
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects. Cancer Treat Rev (1995) 0.97
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol (1994) 0.95
Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer (1995) 0.91
Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surv (1993) 0.87
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet (2001) 6.11
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol (2001) 4.89
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer (2001) 4.49
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol (1999) 3.62
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer (2002) 3.26
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer (2006) 3.15
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol (2000) 3.04
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol (2002) 2.87
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res (2001) 2.64
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol (2001) 2.52
Socio-economic deprivation and stage of disease at presentation in women with breast cancer. Ann Oncol (2000) 2.45
OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther (2012) 2.43
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res (1999) 2.06
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2001) 1.99
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer (2001) 1.96
Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther (2009) 1.94
Mike Grace talks to Penny Vasey. Br Dent J (1996) 1.93
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer (2001) 1.91
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer (1997) 1.88
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol (2000) 1.77
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer (2003) 1.75
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol (1998) 1.72
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer (2003) 1.70
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer (2005) 1.69
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol (2001) 1.62
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol (1995) 1.61
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol (1998) 1.61
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer (1996) 1.58
Role of formulation vehicles in taxane pharmacology. Invest New Drugs (2001) 1.58
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res (1999) 1.57
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer (2008) 1.57
Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res (2000) 1.57
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.56
Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther (2008) 1.54
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) Clin Cancer Res (1999) 1.54
miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene (2012) 1.54
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer (2001) 1.52
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours. Br J Cancer (1998) 1.51
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. J Natl Cancer Inst (1996) 1.49
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol (2003) 1.48
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer (2004) 1.44
Peripheral neurotoxicity induced by docetaxel. Neurology (1996) 1.42
Phase II study of carboplatin and etoposide as a first line regimen in patients with metastatic breast cancer. Ann Oncol (1994) 1.41
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer (2002) 1.41
Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol (2001) 1.38
Systematic review on the use of systemic anticancer therapy in renal-impaired gynecological cancer patients. Int J Gynecol Cancer (2007) 1.38
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer (2001) 1.37
Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer (1993) 1.36
Characterization and use of a digital light projector for vision research. Vision Res (2001) 1.33
Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. J Pharmacol Exp Ther (1989) 1.33
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol (1996) 1.33
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer (2003) 1.32
Lessons learned from independent central review. Eur J Cancer (2009) 1.30
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med (1990) 1.29
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther (2007) 1.28
Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 1.25